Seattle Genetics, Inc. (Nasdaq: SGEN) highlighted several anticipated 2014 milestones related to ADCETRIS (brentuximab vedotin) and its antibody-drug conjugate (ADC) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE